Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of intravenous BMS-986231 in hospitalized acute decompensated heart failure
NL-OMON46946Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cimlanod in Acute Heart Failure (AHF) and heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of clinically relevant hypotension. Started Aug 2017; status: completed.
02
Drugs
cimlanod
03
Conditions
Acute Heart Failure (AHF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON46946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46946.